Reuters logo
BRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients
September 22, 2017 / 10:15 PM / a month ago

BRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients

Sept 22 (Reuters) - Bristol-myers Squibb Co :

* Bristol-Myers Squibb’S Opdivo (Nivolumab) receives FDA approval for the treatment of Hepatocellular Carcinoma patients previously treated with Sorafenib

* ‍U.S. FDA approved Opdivo (Nivolumab) injection for intravenous use for treatment of patients with HCC previously treated with Sorafenib​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below